Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).
- Mechanism
- Curator reviewed
Pumactant is known as a lung (pulmonary) surfactant. Surfactants are wetting agents which coat the surface of the air sacs (alveoli) and reduce surface tension in the lungs. This helps to inflate and expand the air sacs during breathing and prevents their collapse. Surfactants are normally produced naturally in the lungs. A failure by the lungs to do this results in a life threatening disorder known as respiratory distress syndrome, where the lungs become stiff, uninflatable and make breathing extremely difficult. This commonly occurs in premature babies, where their under-developed lungs are incapable of producing surfactants. Pumactant is given directly into the lung through a tube (endotracheal administration), to replace the natural surfactant and therefore aids breathing in premature babies.
- Primary indication
- Investigated for use/treatment in asthma, lung injury, and surgical adhesions.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which companies are running trials of Pumactant, in which indications and phases, and which of those programs are still active?